FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385751336> ?p ?o ?g. }

• W4385751336 endingPage "130" @default.
• W4385751336 startingPage "125" @default.
• W4385751336 abstract "To describe the behavior of total alkaline phosphatase (tALP) in patients with metastatic castration-resistant prostate cancer receiving radium-223 therapy, in a real-world scenario, and to describe overall survival (OS) among such patients.This was a retrospective study involving 97 patients treated between February 2017 and September 2020. Patients were stratified by the baseline tALP (normal/elevated). A tALP response was defined as a ≥ 30% reduction from baseline at week 12. For patients with elevated baseline tALP, we also evaluated treatment response as a ≥ 10% reduction in tALP after the first cycle of treatment. We defined OS as the time from the first treatment cycle to the date of death.There was a significant reduction in the median tALP after each cycle of treatment (p < 0.05 for all). Data for tALP at week 12 were available for 71 of the 97 patients. Of those 71 patients, 26 (36.6%) responded. Elevated baseline tALP was observed in 47 patients, of whom 19 (40.4%) showed a response. Longer OS was observed in the patients with normal baseline tALP, in those with elevated baseline tALP that showed a response to treatment (≥ 10% reduction), and in those who received 5-6 cycles of therapy.The tALP may be used to predict which patients will benefit from treatment with a greater number of cycles of radium-223 therapy and will have longer OS.Descrever o comportamento da fosfatase alcalina total (tALP) em pacientes com carcinoma de próstata metastático resistente a castração, submetidos a terapia com rádio-223 em um cenário do mundo real, e a sobrevida global (SG) desses pacientes.Estudo retrospectivo envolvento 97 pacientes, no período de fevereiro/2017 a setembro/2020. Os pacientes foram estratificados de acordo com a tALP basal (normal/elevada). A resposta à tALP foi definida como uma redução em relação à linha de base de ≥ 30% na semana-12. Para pacientes com tALP basal elevada, também foi avaliada a resposta ao tratamento como uma redução de ≥ 10% de tALP após o primeiro ciclo. A SG foi definida como o tempo entre o primeiro ciclo e a data do óbito.A redução da tALP média após cada ciclo foi significativa (p < 0,05). A tALP na semana 12 estava disponível para 71 dos 97 pacientes. Desses 71 pacientes, 26 (36,6%) responderam. Dezenove (40,4%) dos 47 pacientes com tALP elevada apresentaram resposta. Foi observada uma SG mais longa nos pacientes com tALP basal normal, nos pacientes com tALP basal elevada que apresentaram resposta ao tratamento (redução de ≥ 10%) e nos pacientes que receberam 5-6 ciclos.A tALP pode ser usada para prever parte dos pacientes que se beneficiarão do tratamento com um maior número de ciclos e uma SG mais longa." @default.
• W4385751336 created "2023-08-12" @default.
• W4385751336 creator A5010153847 @default.
• W4385751336 creator A5017795515 @default.
• W4385751336 creator A5029778050 @default.
• W4385751336 creator A5035409886 @default.
• W4385751336 creator A5045762024 @default.
• W4385751336 creator A5092627593 @default.
• W4385751336 date "2023-06-01" @default.
• W4385751336 modified "2023-09-25" @default.
• W4385751336 title "Behavior of total alkaline phosphatase after radium-233 therapy in metastatic castration-resistant prostate cancer: a single-center, real-world retrospective study" @default.
• W4385751336 cites W2010618769 @default.
• W4385751336 cites W2014006626 @default.
• W4385751336 cites W2049857302 @default.
• W4385751336 cites W2076668534 @default.
• W4385751336 cites W2141454098 @default.
• W4385751336 cites W2588172683 @default.
• W4385751336 cites W2604062834 @default.
• W4385751336 cites W2781780556 @default.
• W4385751336 cites W2799375096 @default.
• W4385751336 cites W2801850987 @default.
• W4385751336 cites W2808762102 @default.
• W4385751336 cites W2839363354 @default.
• W4385751336 cites W2946986050 @default.
• W4385751336 cites W2974886802 @default.
• W4385751336 cites W2981260845 @default.
• W4385751336 cites W3005906688 @default.
• W4385751336 cites W3013894168 @default.
• W4385751336 cites W3015310737 @default.
• W4385751336 cites W3022141926 @default.
• W4385751336 cites W3041453910 @default.
• W4385751336 cites W3101707942 @default.
• W4385751336 cites W3111067942 @default.
• W4385751336 cites W3116142907 @default.
• W4385751336 cites W3131644251 @default.
• W4385751336 cites W3134766907 @default.
• W4385751336 cites W4210490878 @default.
• W4385751336 cites W4288084806 @default.
• W4385751336 doi "https://doi.org/10.1590/0100-3984.2022.0080" @default.
• W4385751336 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37564085" @default.
• W4385751336 hasPublicationYear "2023" @default.
• W4385751336 type Work @default.
• W4385751336 citedByCount "0" @default.
• W4385751336 crossrefType "journal-article" @default.
• W4385751336 hasAuthorship W4385751336A5010153847 @default.
• W4385751336 hasAuthorship W4385751336A5017795515 @default.
• W4385751336 hasAuthorship W4385751336A5029778050 @default.
• W4385751336 hasAuthorship W4385751336A5035409886 @default.
• W4385751336 hasAuthorship W4385751336A5045762024 @default.
• W4385751336 hasAuthorship W4385751336A5092627593 @default.
• W4385751336 hasBestOaLocation W43857513361 @default.
• W4385751336 hasConcept C121608353 @default.
• W4385751336 hasConcept C126322002 @default.
• W4385751336 hasConcept C126894567 @default.
• W4385751336 hasConcept C141071460 @default.
• W4385751336 hasConcept C143998085 @default.
• W4385751336 hasConcept C167135981 @default.
• W4385751336 hasConcept C2777783956 @default.
• W4385751336 hasConcept C2780192828 @default.
• W4385751336 hasConcept C2780737065 @default.
• W4385751336 hasConcept C71924100 @default.
• W4385751336 hasConceptScore W4385751336C121608353 @default.
• W4385751336 hasConceptScore W4385751336C126322002 @default.
• W4385751336 hasConceptScore W4385751336C126894567 @default.
• W4385751336 hasConceptScore W4385751336C141071460 @default.
• W4385751336 hasConceptScore W4385751336C143998085 @default.
• W4385751336 hasConceptScore W4385751336C167135981 @default.
• W4385751336 hasConceptScore W4385751336C2777783956 @default.
• W4385751336 hasConceptScore W4385751336C2780192828 @default.
• W4385751336 hasConceptScore W4385751336C2780737065 @default.
• W4385751336 hasConceptScore W4385751336C71924100 @default.
• W4385751336 hasIssue "3" @default.
• W4385751336 hasLocation W43857513361 @default.
• W4385751336 hasLocation W43857513362 @default.
• W4385751336 hasOpenAccess W4385751336 @default.
• W4385751336 hasPrimaryLocation W43857513361 @default.
• W4385751336 hasRelatedWork W122177069 @default.
• W4385751336 hasRelatedWork W2002120878 @default.
• W4385751336 hasRelatedWork W2003938723 @default.
• W4385751336 hasRelatedWork W2047967234 @default.
• W4385751336 hasRelatedWork W2118496982 @default.
• W4385751336 hasRelatedWork W2439875401 @default.
• W4385751336 hasRelatedWork W2568045406 @default.
• W4385751336 hasRelatedWork W2996229517 @default.
• W4385751336 hasRelatedWork W4238867864 @default.
• W4385751336 hasRelatedWork W2525756941 @default.
• W4385751336 hasVolume "56" @default.
• W4385751336 isParatext "false" @default.
• W4385751336 isRetracted "false" @default.
• W4385751336 workType "article" @default.